Last reviewed · How we verify
Intralipid, 20% Intravenous Emulsion
At a glance
| Generic name | Intralipid, 20% Intravenous Emulsion |
|---|---|
| Also known as | Intralipid 20% Reduction, Intralipid 20% Historic, 20% i.v. fat emulsion, lipofundin 20 |
| Sponsor | University of Copenhagen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Low Dose Fat-Induced Insulin Resistance (EARLY_PHASE1)
- Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses (PHASE2)
- Intralipid® 20% for Reversal of Local Anesthetics (PHASE4)
- Does Intralipid Infusion Can Reverse the Spinal Anesthesia Effect in Day Case Surgery? (NA)
- Role of Intralipid in Management of Organophosphorus Poisoning (PHASE2, PHASE3)
- A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses (PHASE2)
- Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates (PHASE3)
- Bioequivalence Study of Propofol Medium and Long Chain Fat Emulsion Injection in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intralipid, 20% Intravenous Emulsion CI brief — competitive landscape report
- Intralipid, 20% Intravenous Emulsion updates RSS · CI watch RSS
- University of Copenhagen portfolio CI